John A. Thompson

17.7k total citations · 5 hit papers
123 papers, 11.2k citations indexed

About

John A. Thompson is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, John A. Thompson has authored 123 papers receiving a total of 11.2k indexed citations (citations by other indexed papers that have themselves been cited), including 82 papers in Oncology, 62 papers in Immunology and 34 papers in Molecular Biology. Recurrent topics in John A. Thompson's work include CAR-T cell therapy research (45 papers), Immunotherapy and Immune Responses (43 papers) and Cancer Immunotherapy and Biomarkers (43 papers). John A. Thompson is often cited by papers focused on CAR-T cell therapy research (45 papers), Immunotherapy and Immune Responses (43 papers) and Cancer Immunotherapy and Biomarkers (43 papers). John A. Thompson collaborates with scholars based in United States, France and Netherlands. John A. Thompson's co-authors include Robert J. Motzer, Robert A. Figlin, Thomas E. Hutson, Stéphane Oudard, Bernard Escudier, Viktor Grünwald, Sergio Bracarda, Alain Ravaud, Camillo Porta and Andrea Kay and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of the American Chemical Society.

In The Last Decade

John A. Thompson

121 papers receiving 11.0k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

2008 2.3k citations Robert J. Motzer, Bernard Escudier et al. The Lancet profile →
Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

2009 1.7k citations Robert J. Motzer, Thomas E. Hutson et al. Journal of Clinical Oncology profile →
Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1999 919 citations Cassian Yee, Jeffrey S. Weber et al. profile →
Phase 3 trial of everolimus for metastatic renal cell carcinoma

2010 903 citations Robert J. Motzer, Bernard Escudier et al. profile →
Guidelines of care for the management of primary cutaneous melanoma

2018 393 citations John A. Thompson et al. profile →

Peers

Countries citing papers authored by John A. Thompson

Since Specialization

Citations

This map shows the geographic impact of John A. Thompson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John A. Thompson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John A. Thompson more than expected).

Fields of papers citing papers by John A. Thompson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John A. Thompson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John A. Thompson. The network helps show where John A. Thompson may publish in the future.

Co-authorship network of co-authors of John A. Thompson

This figure shows the co-authorship network connecting the top 25 collaborators of John A. Thompson. A scholar is included among the top collaborators of John A. Thompson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John A. Thompson. John A. Thompson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	2758MO Updated results from a phase I/II study of gocatamig for small cell lung cancer (SCLC) and other neuroendocrine cancers 2025 ·Annals of Oncology ·Himisha Beltran, (unknown), Prantesh Jain, Erin L. Schenk, Rachel E. Sanborn, John A. Thompson, (unknown), Hirva Mamdani, Rahul Aggarwal, K. Nathan Sankar, (unknown), Vassiliki Karantza, Aiguo Wang, Ann W. Gramza, (unknown)	0
2	Prehospital Experience With Left Ventricular Assist Devices 2025 ·Journal of Surgical Research ·(unknown), (unknown), (unknown), Raymond Zhang, John A. Thompson, (unknown), Asa Margolis, (unknown)	1
3	691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation 2024 ·Annals of Oncology ·Alison M. Schram, Gilberto Lopes, (unknown), Elisa Fontana, Thomas B. Karasic, (unknown), Patricia LoRusso, Vanesa Gregorc, (unknown), (unknown), Dominic Richardson, (unknown), Alexander I. Spira, Daniel Shao-Weng Tan, John A. Thompson, Dipesh Uprety, Marc Fellous, Yanguo Qin, Ecaterina E. Dumbrava	2
4	Immune Checkpoint Inhibitor–Induced Colitis 2024 ·Gastroenterology ·Anusha Shirwaikar Thomas, Lu Yang, (unknown), John A. Thompson, Dongfeng Tan, David M. Faleck, Yinghong Wang	1
5	Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis 2023 ·Journal for ImmunoTherapy of Cancer ·Yousef R. Badran, Fangwen Zou, Sienna Durbin, (unknown), Hamzah Abu‐Sbeih, Anusha Shirwaikar Thomas, Mehmet Altan, John A. Thompson, Wei Qiao, Donna Leet, (unknown), Nora Horick, Michael A. Postow, David M. Faleck, Yinghong Wang, Michael Dougan	17
6	Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: review of the literature and personalized risk-based prevention strategy 2020 ·Annals of Oncology ·John B.A.G. Haanen, Marc S. Ernstoff, Yinghong Wang, Alexander M. Menzies, Igor Puzanov, Petros Grivas, James Larkin, Solange Peters, John A. Thompson, Michel Obéid	153
7	New therapeutic perspectives to manage refractory immune checkpoint-related toxicities 2019 ·The Lancet Oncology ·Filipe Martins, Gerasimos P. Sykiotis, Michel H. Maillard, Montserrat Fraga, Camillo Ribi, Thierry Küntzer, Olivier Michielin, Solange Peters, George Coukos, François Spertini, John A. Thompson, Michel Obéid	141
8	Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study 2018 ·Clinical Cancer Research ·Michael B. Atkins, F. Stephen Hodi, John A. Thompson, Ray McDermott, Wen‐Jen Hwu, Donald P. Lawrence, Nancy A. Dawson, (unknown), Shailender Bhatia, (unknown), Lokesh Jain, Seth Robey, Xinxin Shu, Blanca Homet Moreno, Rodolfo F. Perini, Toni K. Choueiri, Antoni Ribas	48
9	A Single Direct Intratumoral Injection of TTI-621 (SIRPαFc) Induces Antitumor Activity in Patients with Relapsed/Refractory Mycosis Fungoides and Sézary Syndrome: Preliminary Findings Employing an Immune Checkpoint Inhibitor Blocking the CD47 Do Not Eat Signal 2017 ·Blood ·Christiane Querfeld, John A. Thompson, Matthew H. Taylor, Raju Pillai, Lisa D. Johnson, (unknown), Penka S. Petrova, Robert A. Uger, (unknown), Eric L. Sievers, Oleg E. Akilov	15
10	Safety, pharmacokinetics (PK) and pharmacodynamics (PD) data from a phase I dose-escalation study of OX40 agonistic monoclonal antibody (mAb) PF-04518600 (PF-8600) in combination with utomilumab, a 4-1BB agonistic mAb 2017 ·Annals of Oncology ·Omid Hamid, Willeke Ros, John A. Thompson, Siwen Hu‐Lieskovan, Fredericus Eskens, Adi Diab, Toshihiko Doi, Jeffrey S. Wasser, (unknown), Naiyer A. Rizvi, Eric Angevin, Alberto Chiappori, Patrick A. Ott, Bishu Ganguly, Catherine Fleener, (unknown), Kuo‐Wei Liao, Tenshang Joh, Jeffrey Chou, (unknown)	2
11	Combined IL-21–primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient 2016 ·The Journal of Experimental Medicine ·Aude G. Chapuis, Sylvia M. Lee, John A. Thompson, Ilana M. Roberts, Kim Margolin, Shailender Bhatia, (unknown), Ivy Lai, Felecia Wagener, Kendall C. Shibuya, Jianhong Cao, Jedd D. Wolchok, Philip D. Greenberg, Cassian Yee	68
12	A first-in-human (FIH) study of PF-04518600 (PF-8600) OX40 agonist in adult patients (pts) with select advanced malignancies 2016 ·Annals of Oncology ·Adi Diab, Anthony B. El-Khoueiry, Ferry A.L.M. Eskens, Willeke Ros, John A. Thompson, Cyril Konto, (unknown), Tenshang Joh, Kuo‐Wei Liao, Bishu Ganguly, Omid Hamid	12
13	A phase 2 randomised study of ramucirumab (IMC-1121B) with or without dacarbazine in patients with metastatic melanoma 2014 ·European Journal of Cancer ·Richard D. Carvajal, Michael K. Wong, John A. Thompson, Michael S. Gordon, Karl D. Lewis, Anna C. Pavlick, Jedd D. Wolchok, (unknown), Jonathan D. Schwartz, Agop Y. Bedikian	22
14	Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma 2014 ·Investigational New Drugs ·Nizar M. Tannir, Andres Forero‐Torres, Radhakrishnan Ramchandren, Sumanta K. Pal, Stephen M. Ansell, Jeffrey R. Infante, Sven de Vos, Paul A. Hamlin, Stella K. Kim, Nancy Whiting, Elaina M. Gartner, Baiteng Zhao, John A. Thompson	97
15	Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma breakdown → 2009 ·Journal of Clinical Oncology ·Robert J. Motzer, Thomas E. Hutson, Piotr Tomczak, M. Dror Michaelson, Ronald M. Bukowski, Stéphane Oudard, Sylvie Négrier, Cezary Szczylik, Роберто Пили, Georg A. Bjarnason, Xavier García del Muro, Jeffrey A. Sosman, E Solska, George Wilding, John A. Thompson, Sindy T. Kim, Isan Chen, Xin Huang, Robert A. Figlin	1711
16	A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma 2009 ·Clinical Cancer Research ·Jeffrey S. Weber, John A. Thompson, Omid Hamid, David R. Minor, Asim Amin, Ilan G. Ron, Ruggero Ridolfi, Hazem Assi, Anthony Maraveyas, David M. Berman, Jonathan Siegel, Steven O’Day	460
17	C19orf48 Encodes a Minor Histocompatibility Antigen Recognized by CD8+ Cytotoxic T Cells from Renal Cell Carcinoma Patients 2008 ·Clinical Cancer Research ·Scott S. Tykodi, Nobuharu Fujii, Nathalie Vigneron, Sharon Lu, Jeffrey K. Mito, (unknown), Jeffrey Chou, Lilien N. Voong, John A. Thompson, Brenda M. Sandmaier, Peter Cresswell, Benoı̂t Van den Eynde, Stanley R. Riddell, Edus H. Warren	43
18	Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial breakdown → 2008 ·The Lancet ·Robert J. Motzer, Bernard Escudier, Stéphane Oudard, Thomas E. Hutson, Camillo Porta, Sergio Bracarda, Viktor Grünwald, John A. Thompson, Robert A. Figlin, Norbert Hollaender, Gladys Urbanowitz, William J. Berg, Andrea Kay, David Lebwohl, Alain Ravaud	2339
19	Intralesional targeted alpha therapy for metastatic melanoma 2005 ·Cancer Biology & Therapy ·Barry Allen, Chand Raja, Syed Rizvi, Yong Li, Wendy Tsui, Peter Graham, John A. Thompson, Ralph A. Reisfeld, John H. Kearsley, Aliyah Morgenstern, Christos Apostolidis	96
20	Inter- and intramolecular deuterium isotope effects on the cytochrome P-450-catalyzed oxidative dehalogenation of 1,1,2,2-tetrachloroethane 1987 ·Biochemical and Biophysical Research Communications ·Dale B. Hales, (unknown), John A. Thompson	8

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact